People · Operator
Named in public records as an officer, director or promoter · active 2015–2024 · Biotechnology, Other Technology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Zura Bio Ltd | — | Biotechnology | Series D+ | $128.4M | $1.3B | 2023 |
| Dolly, Inc. | — | Other Technology | Series A | $22.3M | $259.0M | 2015 |
| Amytrx Therapeutics, Inc. | — | Pharmaceuticals | Seed | $7.0M | $4.6M | 2023 |
Michael Howell at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Michael Howell on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| JASON STOFFER | 1 | 11 |
| Andy Liu | 1 | 9 |
| Amit Munshi | 1 | 5 |
| Lawrence W> Greer | 1 | 4 |
| Dennis Carlo | 1 | 2 |
| Kim Davis | 1 | 2 |
| Sandeep Kulkarni | 1 | 2 |
| Dennis J. Carlo | 1 | 2 |
| Matthew A Gonda | 1 | 2 |
| Steven Schoch | 1 | 2 |
| Thomas G. Andrews | 1 | 2 |
| Jennifer Jarrett | 1 | 1 |
| Someit Sidhu | 1 | 1 |
| Arnout Ploos Van Amstel | 1 | 1 |
| Parvinder Thiara | 1 | 1 |
| Garry Neil | 1 | 1 |
| Christopher Cabell | 1 | 1 |
| Matthew Gonda | 1 | 1 |
| Lawrence Greer | 1 | 1 |
| Satish Joshi | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.